The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 35-45 % of colorectal cancer (CRC) cases. Although the association between the RAS signaling and angiogenesis is well known, the negative predictive value of KRAS mutation has not been established in patients treated with bevacizumab. The aim of this study was to evaluate the association between specific KRAS mutation types and outcome of patients with metastatic CRC treated with bevacizumab. The study included 404 patients with metastatic CRC (mCRC) treated with bevacizumab. Clinical data obtained from the clinical registry CORECT were retrospectively analyzed. The shortest survival was observed in patients with tumors harboring G12V or G12A KRAS mutation (G12V/A). The median progression-free survival (PFS) and overall survival (OS) for patients with tumors harboring G12V/A KRAS mutation was 6.6 and 16.8 compared to 11.6 and 26.3 months for patients with tumors harboring other KRAS mutation type (p < 0.001 and p < 0.001), while the survival of patients harboring other KRAS mutation types was comparable to those with tumors harboring wild-type KRAS gene. In the Cox multivariable analysis, KRAS G12V/A mutation type remains a significant factor predicting both PFS (HR = 2.18, p < 0.001) and OS (HR = 2.58, p < 0.001). In conclusion, the results of the present study indicate that there is a significant difference in biological behavior between tumors harboring G12V/A and other KRAS mutations. Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses.

Biomedical Center Faculty of Medicine in Pilsen Charles University Prague Plzeň Czech Republic

Bioptic Laboratory Ltd Molecular Pathology Laboratory Plzeň Czech Republic

Department of Nuclear Medicine Medical School and Teaching Hospital Pilsen Charles University Prague Pilsen Czech Republic

Department of Oncology and 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Oncology and Radiotherapy Medical School and Teaching Hospital Pilsen Charles University Prague alej Svobody 80 CZ 304 60 Pilsen Czech Republic

Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Surgery Medical School and Teaching Hospital Pilsen Charles University Prague Pilsen Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

J Clin Oncol. 2011 Jul 1;29(19):2675-82 PubMed

BMC Gastroenterol. 2015 Mar 24;15:37 PubMed

Int J Oncol. 1996 Dec;9(6):1307-11 PubMed

J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 PubMed

Nagoya J Med Sci. 2012 Aug;74(3-4):261-71 PubMed

J Clin Oncol. 2008 Apr 20;26(12):2013-9 PubMed

N Engl J Med. 2004 Jun 3;350(23 ):2335-42 PubMed

Nature. 1999 Jul 29;400(6743):468-72 PubMed

J Clin Oncol. 2008 Apr 1;26(10 ):1626-34 PubMed

J Natl Cancer Inst. 1998 May 6;90(9):675-84 PubMed

Cancer Res. 2006 Apr 15;66(8):3992-5 PubMed

Cancer Res. 2000 Jan 15;60(2):490-8 PubMed

Oncologist. 2009 Sep;14(9):862-70 PubMed

Br J Cancer. 2006 Jan 30;94(2):318-22 PubMed

N Engl J Med. 2008 Oct 23;359(17):1757-65 PubMed

J Pathol. 1999 Mar;187(4):433-8 PubMed

Cancer Metastasis Rev. 1995 Dec;14(4):263-77 PubMed

Cancer Res. 1989 Sep 1;49(17):4682-9 PubMed

Adv Cancer Res. 1996;69:135-74 PubMed

J Clin Oncol. 2009 Feb 10;27(5):672-80 PubMed

Carcinogenesis. 2006 Nov;27(11):2190-200 PubMed

Cancer Res. 1998 Mar 15;58(6):1149-58 PubMed

Ann Oncol. 2009 Nov;20(11):1842-7 PubMed

Cancer Cell. 2003 Mar;3(3):219-31 PubMed

Br J Cancer. 2001 Sep 1;85(5):692-6 PubMed

Pathol Res Pract. 2009;205(12 ):858-62 PubMed

J Natl Cancer Inst. 2005 Jul 6;97(13):981-9 PubMed

BMC Med. 2013 Mar 04;11:59 PubMed

J Clin Oncol. 2005 Jun 1;23(16):3706-12 PubMed

J Biomed Biotechnol. 2010;2010:150960 PubMed

Carcinogenesis. 2003 Apr;24(4):703-10 PubMed

Cancer Res. 1995 Oct 15;55(20):4575-80 PubMed

J Pathol. 1998 Jun;185(2):130-8 PubMed

PLoS One. 2012;7(10):e47345 PubMed

CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 PubMed

Cancer Res. 2007 Mar 15;67(6):2643-8 PubMed

Oncologist. 2009 Jan;14 (1):22-8 PubMed

Med Oncol. 2013;30(3):650 PubMed

J Clin Oncol. 2008 Jan 20;26(3):374-9 PubMed

Nat Rev Cancer. 2003 Jun;3(6):459-65 PubMed

J Clin Oncol. 2001 Jan 15;19(2):299-304 PubMed

Oncol Rep. 2009 May;21(5):1283-7 PubMed